Highbridge Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Highbridge Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-300,000	Closed	-$28.5M	–	93
2019 Q4	$28.5M	Buy	+300,000	New	+$25.9M	3.16%	9
2019 Q3	–	Sell	-200,000	Closed	-$17.5M	–	131
2019 Q2	$17.5M	Sell	200,000 -450,000	-69%	-$38.4M	1.16%	31
2019 Q1	$58.9M	Buy	+650,000	New	+$55.3M	1.81%	5
2018 Q3	–	Sell	-150,000	Closed	-$14.3M	–	899
2018 Q2	$14.3M	Sell	150,000 -75,000	-33%	-$6.89M	0.29%	84
2018 Q1	$19.7M	Buy	+225,000	New	+$20.5M	0.32%	64

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Highbridge Capital Management's XBI Position: Q1 2019 in Review

Highbridge Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2019, closing a stake of 90,000 shares — an estimated $7.66M sold.

Highbridge Capital Management first reported a position in XBI in Q2 2017 and held it in 2 quarters. The position peaked at $6.46M in Q4 2018. 451 funds tracked by Wall St. Rank hold XBI as of Q1 2019.

Highbridge Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2019 after selling out during the quarter.
Highbridge Capital Management sold 90,000 State Street SPDR S&P Biotech ETF shares in Q1 2019, an estimated $7.66M.
Highbridge Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and held it in 2 quarters.
Highbridge Capital Management's State Street SPDR S&P Biotech ETF position peaked at $6.46M in Q4 2018.
451 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2019.

Based on Highbridge Capital Management's 13F filing for Q1 2019, filed 15 May 2019.